Stifel Cuts Treace Medical Concepts Price Target 40% to $3
Stifel reduced its Treace Medical Concepts price target by 40% to $3 from $5 while keeping a Hold rating, reflecting sector-wide recalibration following 2025 pressures. The company reported third-quarter 2025 revenue of $50.2 million, up 11% year-over-year, and is investing in product expansion, surgeon training and sales capacity.
1. Price Target Revision
On January 7, Stifel lowered its price target for Treace Medical Concepts to $3 from $5 and maintained a Hold rating, citing MedTech sector pressures in 2025 and a broader coverage recalibration.
2. Third-Quarter Financial Results
In Q3 2025, Treace reported revenue of $50.2 million, marking 11% year-over-year growth, driven by steady procedure volumes and market adoption of its Lapiplasty solutions.
3. Strategic Growth Initiatives
Management plans to expand the product portfolio, enhance surgeon education and training programs, and strengthen the sales organization to capture additional market share and improve profitability as demand normalizes.